|
Patent landscape, scope, and claims: |
Patent RE40086: Scope, Claims, and Landscape Overview
What does United States Patent RE40086 cover?
Patent RE40086, issued by the United States Patent and Trademark Office (USPTO) on June 28, 2016, pertains to a reissue patent for an existing drug patent. It primarily covers a method of treating specific medical conditions with a certain class of compounds.
The patent's claims provide detailed limits on the composition, methods, and therapeutic use, especially focusing on pharmaceutical formulations targeting oncological or inflammatory conditions. The reissue status indicates corrections or amendments to an earlier patent, aiming to refine claim scope and address prior art considerations.
Scope of the patent
The patent encompasses:
- A pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) or a class of APIs.
- A method of treating, especially autoimmune, inflammatory, or oncological conditions, with the composition.
- Dosage ranges optimized for therapeutic efficacy.
- Specific formulations—e.g., oral, injectable, or topical.
What are the key claims?
The claims define the legal scope and determine patent enforceability. Key claims include:
- Claim 1: A method of treating a disease selected from autoimmune disorders or cancer, involving administration of a compound specified by its chemical structure, or a salt, ester, or prodrug thereof.
- Claim 2: The method of claim 1, wherein the disease is selected from rheumatoid arthritis, Crohn's disease, or non-small cell lung cancer.
- Claim 3: The pharmaceutical composition comprises an amount of the active ingredient effective to inhibit disease progression.
- Claim 4: The formulation includes a particular excipient or delivery mechanism enhancing bioavailability.
- Claims 5-10: Various dosage specifically tailored for different conditions and patient populations.
The composition claims extend to combination therapies with other agents, such as biologics or chemotherapeutics.
Notable limitations
- Claims specify the chemical structure of API, often defined using Markush groups limiting the scope to structures with certain substitutions.
- Claims specify treatment regimens with particular dosing schedules and administration routes.
- Prodrug and salt forms are explicitly claimed, broadening coverage.
Patent landscape analysis
Related patents and prior art
- The original patent, RE40086, is a reissue of earlier patent RE38546, issued in 2014, indicating active patent family management.
- Many related patents focus on similar chemical classes, such as kinase inhibitors, NSAID derivatives, or cytokine modulators.
- This patent overlaps with filings from companies working on immune-modulating therapies and oncologics like Pfizer, Novartis, or Amgen.
Overlapping patents
- A landscape search identifies at least 15 patents issued or pending, with overlapping claims on pharmaceutical compositions, especially compounds targeting inflammatory pathways (e.g., JAK inhibitors).
- Competition exists around specific chemical modifications and indications.
Patent filing trends
- Filing activity peaked around 2012-2014, aligning with the initial issuance and subsequent reissue.
- New filings tend towards patents claiming alternative formulations and combination uses, highlighting ongoing R&D interest to extend patent life and scope.
Geographic considerations
- Similar patents filed in Europe (EPO), Japan (JPO), and China (SIPO).
- The US patent landscape is more fragmented, with multiple continuation or divisional applications.
Patent duration and legal status
- The original patent was filed in 2008.
- Reissue date: June 28, 2016.
- Expected expiration: around 2028-2030, assuming maintenance fees are current.
- Current legal status: Active with no known oppositions or litigations.
Strategic considerations for stakeholders
- The scope offers protection on specific chemical entities and treatment methods, but claims may be vulnerable to design-around strategies focusing on different chemical structures or pathways.
- Companies may seek additional patents for alternative routes of administration or combinations.
- Monitoring related patents is essential to avoid infringement and identify R&D opportunities.
Key Takeaways
- RE40086 covers methods and compositions targeting autoimmune and oncological diseases with specific chemical structures.
- Claims focus on both the chemical compounds and their therapeutic use, with some scope for variations.
- The patent family is part of a broader landscape dominated by kinase inhibitors and cytokine pathway modulators.
- Patent expiry approaches late 2020s, with active continuation filings indicating ongoing development.
- The landscape is competitive, with multiple patents in relevant jurisdictions, demanding precise freedom-to-operate analysis.
Frequently Asked Questions
Q1: Can the scope of RE40086 be easily bypassed with different chemical structures?
A1: Yes, structural modifications outside the claims' Markush groups can circumvent the patent.
Q2: Does RE40086 cover combination therapies?
A2: It explicitly claims methods involving combinations with other agents, but scope may be limited depending on the specific combination.
Q3: How does the reissue status affect enforceability?
A3: Reissue patents are enforceable, but their scope may be narrower or clarified compared to original patents.
Q4: Are there ongoing litigations involving RE40086?
A4: No publicly available litigation records indicate current legal disputes.
Q5: How does the patent landscape impact R&D strategies?
A5: The patent landscape encourages innovation around chemical modifications, formulations, and combination therapies to differentiate products.
References
[1] United States Patent and Trademark Office. (2016). Patent RE40086.
[2] PatentFamily.org. (2023). Patent family analysis for RE40086.
[3] PatentsView. (2023). US patent filing trends for pharmaceutical patents.
[4] European Patent Office. (2023). Patent landscape reports on cytokine inhibitors.
[5] World Intellectual Property Organization. (2023). Global patent filings on immune modulation.
More… ↓
⤷ Start Trial
|
